EMA Authorised: Hympavzi (marstacimab) — Pfizer Europe MA EEIG

View source ↗

Summary

EMA authorised Hympavzi (marstacimab) for hemophilia A and B, expanding treatment options for these conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia
• Hemophilia B

Drugs mentioned

• HYMPAVZI (MARSTACIMAB-HNCQ)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A;Hemophilia B. MAH: Pfizer Europe MA EEIG. Decision date: 11/05/2026